FAMVIR
LOE ApproachingNDAORALTABLET
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FAMVIR is an oral small-molecule antiviral approved in 1994 for herpes virus infections. The drug is administered as a tablet and represents a mature, established therapy in the antiviral space. Specific mechanism of action and indication details are not available in current data.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team is likely consolidating around retention and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FAMVIR currently shows zero linked job openings, reflecting its late-lifecycle status under Novartis. Working on this product offers stability in a mature market but limited career growth opportunities compared to growth-stage brands.
Brand ManagerProduct Manager
Worked on FAMVIR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.